Moderna’s share price has been under pressure despite approvals for its coronavirus vaccine. Does this represent a buying opportunity, or has the stock climbed too high, too fast?
Multiple small-and mid-cap stocks have exciting stories to tell investors in 2021.
One analyst recommends Olema Pharma, Morphic Holding, and Schrodinger
The biotechnology exchange-traded fund
SPDR S&P Biotech ETF (NYSE: XBI) is up around 50% in 2020 and Jefferies’ managing director Michael Yee says the valuations are not only justified but sustainable in 2021.
‘Exciting stories’ for 2021
While looking at the Biotech sector, it is important to separate the small group of COVID-19 vaccine makers from the overall biotech innovation thesis, Yee said Tuesday on CNBC’s “Closing Bell.” The market is certainly “on board” with the notion that many biotech companies are poised to innovate, grow, and disrupt legacy healthcare and pharmaceutical companies in 2021.
The Washington Post, citing a Centers for Disease Control and Prevention study, reported the number of annual HIV diagnoses has dropped by 19 percent between 2005 and 2014.
Men who have sex with other men accounted for around 67 percent of all HIV diagnoses in 2014.
HIV cases among women fell by. Read More.
Morgan Stanley Downgrades Moderna (MRNA) Stock Before Its Meeting with FDA Today coinspeaker.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from coinspeaker.com Daily Mail and Mail on Sunday newspapers.